US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Medicines

84.90

+0.0000

Volume:- -

Turnover:- -

Market Cap:6.79B

PE:-27.06

High:84.90

Open:84.90

Low:84.90

Close:84.90

Loading ...

Overview Company News Filings

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly

TYK Medicines Reports 2024 Annual Results and Corporate Changes

TYK Medicines Updates Nomination Committee Terms

Press Release: Everest Medicines Announces Financial Results for Full Year Ended December 31, 2024

Everest Medicines Ltd. Releases 2024 Annual Results

Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting

China National Medicines' 2024 Profit Down 7%, Revenue Up 2%

MT Newswires Live

3D Medicines Seeks Patent for Advanced Lipid Nanoparticle Drug Delivery Technology

MT Newswires Live

OS Therapies Schedules United Kingdom’s Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma

Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency (MHRA)

ACCESS Newswire

TYK Medicines Reports Positive Phase II Trial Results for TY-9591

Everest Medicines Shares Surge 18% as First Patient Dosed in Cancer Drug Trial

MT Newswires Live

Jindal Worldwide Divests Entire Stake in Kashyap Tele-Medicines

MT Newswires Live

Praxis Precision Medicines Updates on Programs and Finances

Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences

Revolution Medicines Is Maintained at Buy by HC Wainwright & Co.

Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $65 From $111, Maintains Buy Rating

MT Newswires Live

Everest Medicines Limited's (HKG:1952) biggest owners are retail investors who got richer after stock soared 3.8% last week

Simply Wall St.

Positive Outlook on Praxis Precision Medicines Amidst Phase 3 ET Program Challenges

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MDCO/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MDCO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCO\",,,,,undefined,":{"symbol":"MDCO","market":"US","secType":"STK","nameCN":"Medicines","latestPrice":84.9,"timestamp":1578085200000,"preClose":84.9,"halted":3,"volume":0,"delay":0,"floatShares":74862655,"shares":79948329,"eps":-3.137449,"marketStatus":"Halted","change":0,"latestTime":"01-03 16:00:00 EST","open":84.9,"high":84.9,"low":84.9,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.137449,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":965707200000,"exchange":"NASDAQ","adjPreClose":84.9,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCO\",,,,,undefined,":{"symbol":"MDCO","floatShares":74862655,"roa":"-13.71%","roe":"553.30%","lyrEps":-1.673974,"shares":79948329,"dividePrice":0,"high":84.9,"amplitude":0,"preClose":84.9,"low":84.9,"week52Low":23.15,"pbRate":"178.02","week52High":84.98,"institutionHeld":1.2829,"latestPrice":84.9,"eps":-3.137449,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.137449,"open":84.9,"prevYearClose":84.94},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCO\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522255305","title":"European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11","url":"https://stock-news.laohu8.com/highlight/detail?id=2522255305","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522255305?lang=en_us&edition=fundamental","pubTime":"2025-03-28 18:00","pubTimestamp":1743156000,"startTime":"0","endTime":"0","summary":"SHANGHAI, China & JERSEY CITY, N.J., March 28, 2025----Shanghai Henlius Biotech, Inc.  and Organon  today announced that the European Medicines Agency  has validated the marketing authorization application  for HLX11, an investigational biosimilar of Perjeta . Pertuzumab has been approved in various countries and regions in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory or early-stage breast cancer, and adjuvant treatment for certain HER2-positive early breast cancer, among other indications.In 2022, Henlius entered into a license and supply agreement with Organon, granting Organon the exclusive commercialization rights to two biosimilar candidates, including HLX11. The agreement covers markets such as the United States, the European Union, and Canada. An exception to the agreement is China.Henlius has pro-actively built a diversified and high-quality product pipeline covering about 50 molecules","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/european-medicines-agency-ema-validates-100000495.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065171402.SGD","LU2065169927.USD","BK4559","BK4585","BK4215","MDCO","OGN","BK4007","MAA","BK4588","LU2065171311.SGD","LU2065170008.USD"],"gpt_icon":0},{"id":"2522532250","title":"Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly","url":"https://stock-news.laohu8.com/highlight/detail?id=2522532250","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522532250?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 27, 2025  -- Crinetics Pharmaceuticals, Inc.  today announced that the European Medicines Agency  has validated the Marketing Authorization Application  for paltusotine, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the proposed treatment and long-term maintenance therapy of acromegaly, a serious, rare and progressive endocrine disorder characterized by consistently elevated levels of growth hormone. The MAA will now be reviewed by the Committee for Medicinal Products for Human Use . Additionally, the EMA on February 27, 2025 granted paltusotine Orphan Drug Designation  for the treatment of acromegaly.The EMA grants orphan designation to medicines intended for the treatment, prevention, or diagnosis of life-threatening or chronically debilitating diseases affecting no more than 5 in 10,000 people in the European Union, among other criteria. The medicine must also provide significant benefit to those affected by th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crinetics-pharmaceuticals-announces-european-medicines-200500366.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","BK4588","MDCO","CRNX","BK4215","MAA","CHMP","BK4139","BK4585","BK4535","ODD","BK4551","BK4183","GH","BK4087"],"gpt_icon":0},{"id":"2522228302","title":"TYK Medicines Reports 2024 Annual Results and Corporate Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2522228302","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522228302?lang=en_us&edition=fundamental","pubTime":"2025-03-27 22:18","pubTimestamp":1743085093,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. Class H ( ($HK:2410) ) has provided an announcement. TYK Medicines, Inc announced its annual results for the year ended Decembe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tyk-medicines-reports-2024-annual-results-and-corporate-changes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tyk-medicines-reports-2024-annual-results-and-corporate-changes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO"],"gpt_icon":0},{"id":"2522283302","title":"TYK Medicines Updates Nomination Committee Terms","url":"https://stock-news.laohu8.com/highlight/detail?id=2522283302","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522283302?lang=en_us&edition=fundamental","pubTime":"2025-03-27 22:13","pubTimestamp":1743084828,"startTime":"0","endTime":"0","summary":"An announcement from TYK Medicines, Inc. Class H ( ($HK:2410) ) is now available. TYK Medicines, Inc. has revised the terms of reference for its No...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tyk-medicines-updates-nomination-committee-terms?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tyk-medicines-updates-nomination-committee-terms?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO"],"gpt_icon":0},{"id":"2522863067","title":"Press Release: Everest Medicines Announces Financial Results for Full Year Ended December 31, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2522863067","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522863067?lang=en_us&edition=fundamental","pubTime":"2025-03-26 10:36","pubTimestamp":1742956560,"startTime":"0","endTime":"0","summary":"SHANGHAI, March 25, 2025 /PRNewswire/ -- Everest Medicines , a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative medicines and vaccines, today announced its financial results for the full year ended December 31, 2024, along with a corporate update.\"We continued to advance our pipeline of assets with global rights, focusing on creating value in high-potential therapeutic areas. EVER001, a covalent reversible BTK inhibitor, delivered positive results from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952","BK1583","BK4022","BK4232","MDCO","BK1574","BK1161","R"],"gpt_icon":0},{"id":"2522851429","title":"Everest Medicines Ltd. Releases 2024 Annual Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522851429","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522851429?lang=en_us&edition=fundamental","pubTime":"2025-03-26 08:56","pubTimestamp":1742950566,"startTime":"0","endTime":"0","summary":"The latest update is out from Everest Medicines Ltd. ( ($HK:1952) ). Everest Medicines Ltd. announced its audited annual results for the year endin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/everest-medicines-ltd-releases-2024-annual-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/everest-medicines-ltd-releases-2024-annual-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO"],"gpt_icon":0},{"id":"2521474177","title":"Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2521474177","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521474177?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:00","pubTimestamp":1742817600,"startTime":"0","endTime":"0","summary":"BOSTON, March  24, 2025  (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/24/3047808/0/en/Praxis-Precision-Medicines-to-Present-on-Late-Stage-Programs-across-Epilepsy-and-Movement-Disorders-at-the-American-Academy-of-Neurology-2025-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX","SSI","MDCO","AFG"],"gpt_icon":0},{"id":"2520112378","title":"China National Medicines' 2024 Profit Down 7%, Revenue Up 2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2520112378","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520112378?lang=en_us&edition=fundamental","pubTime":"2025-03-20 10:59","pubTimestamp":1742439591,"startTime":"0","endTime":"0","summary":"China National Medicines  posted 2024 net profit attributable to shareholders of 2.00 billion yuan, or 2.6509 yuan per share, down 6.8% from 2.15 billion yuan, or 2.8443 yuan per share, the previous year.The revenue of the Sinopharm Group  unit climbed 1.8% year over year to 50.6 billion yuan from 49.7 billion yuan, according to a filing with the Shanghai bourse.The company declared a cash dividend of 0.80 per share for 2024.Shares of China National Medicines were down 2% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600511","MDCO","01099","NHLD"],"gpt_icon":0},{"id":"2518236056","title":"3D Medicines Seeks Patent for Advanced Lipid Nanoparticle Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2518236056","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518236056?lang=en_us&edition=fundamental","pubTime":"2025-03-12 15:39","pubTimestamp":1741765173,"startTime":"0","endTime":"0","summary":"3D Medicines  has filed for patent under the Patent Cooperation Treaty for a key component of its ionizable cationic lipid in the lipid nanoparticles for nucleic acid drug delivery, a Tuesday filing with the Hong Kong bourse said.The biopharmaceutical company has created an ionizable cationic lipid R&D platform targeting different cell types and organs by using AI to design and screen hundreds of lipid compounds.The platform synergizes with the development of the firm's self-developed mRNA cancer vaccine projects, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BLZ.SI","BK4157","BK6522","IE00B19Z4B17.USD","MDCO","BK6088","IE00B7SZL793.SGD","IE0031619046.USD","AEIS","IE00B66KJ199.SGD","01244","BK1161"],"gpt_icon":0},{"id":"2518418748","title":"OS Therapies Schedules United Kingdom’s Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2518418748","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518418748?lang=en_us&edition=fundamental","pubTime":"2025-03-11 19:40","pubTimestamp":1741693200,"startTime":"0","endTime":"0","summary":"NEW YORK, March 11, 2025----OS Therapies, Inc. , a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has scheduled a Scientific Advice Meeting  in the third quarter of 2025 to discuss the Innovative Licensing and Access Pathway  with the United Kingdom’s  Medicines and Healthcare products Regulatory Agency  for OST-HER2, its immunotherapy candidate for the prevention of recurrence of metastases in osteosarcoma. The Company released positive Phase 2b data in January 2025 that demonstrates statistically significant results in the primary endpoint of the study, 12-month event free survival . The meeting with MHRA has been scheduled to position the Company to bring OST-HER2 to market in the UK in 2025.\"Today’s announcement marks the beginning of the regulatory process required to bring our OST-HER2 immunotherapy to market globally,\" stated OS Therapies’ CEO Paul Romness. \"As we prepare for regulatory in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/os-therapies-schedules-united-kingdom-114000512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4211","OST","DC","HCSG","OSTX","UK","BK4588","BK4080","BK4137","BK4585","ADC","BK4148","MDCO","BK4158","BK4231","BK4139","BK4017","BK4532","BK4097","BK4233","SAM","BK4205","OS","BK4528","UBCP"],"gpt_icon":0},{"id":"2518816967","title":"Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency (MHRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2518816967","media":"ACCESS Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518816967?lang=en_us&edition=fundamental","pubTime":"2025-03-11 04:01","pubTimestamp":1741636860,"startTime":"0","endTime":"0","summary":"BOULDER, CO / ACCESS Newswire / March 10, 2025 / Sonoma Pharmaceuticals, Inc. , a global healthcare leader developing and producing patented Microcyn technology based stabilized hypochlorous acid  products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the registration of its manufacturing facility and five of its products with the Medicines & Healthcare products Regulatory Agency  in the United Kingdom. The newly registered products include Sonoma's hypochlorous acid-based wound irrigation solution, scar management products, wound hydrogel, and skin exfoliant.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sonoma-pharmaceuticals-secures-extensive-u-200100465.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","HCSG","BK4557","MDCO","SNOA","BK4137"],"gpt_icon":0},{"id":"2518079234","title":"TYK Medicines Reports Positive Phase II Trial Results for TY-9591","url":"https://stock-news.laohu8.com/highlight/detail?id=2518079234","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518079234?lang=en_us&edition=fundamental","pubTime":"2025-03-09 19:59","pubTimestamp":1741521597,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. Class H ( ($HK:2410) ) has provided an announcement. TYK Medicines, Inc announced positive results from its Phase II clinical t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tyk-medicines-reports-positive-phase-ii-trial-results-for-ty-9591?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tyk-medicines-reports-positive-phase-ii-trial-results-for-ty-9591?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TY","MDCO"],"gpt_icon":0},{"id":"2517179442","title":"Everest Medicines Shares Surge 18% as First Patient Dosed in Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2517179442","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517179442?lang=en_us&edition=fundamental","pubTime":"2025-03-07 15:50","pubTimestamp":1741333820,"startTime":"0","endTime":"0","summary":"Everest Medicines  said the first patient was dosed in a clinical trial of its mRNA cancer vaccine EVM16 at Peking University Cancer Hospital,The study aims to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EVM16 as a monotherapy and in combination with a PD-1 antibody in advanced or recurrent solid tumors.The clinical trial of EVM16 is being conducted jointly at Peking University Cancer Hospital and Fudan University Shanghai Cancer Center, according to a Thursday news release.Shares of the biopharmaceutical company soared 18% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO","BK1583","01952","BK1574","BK1161"],"gpt_icon":0},{"id":"2517138868","title":"Jindal Worldwide Divests Entire Stake in Kashyap Tele-Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2517138868","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517138868?lang=en_us&edition=fundamental","pubTime":"2025-03-06 16:23","pubTimestamp":1741249434,"startTime":"0","endTime":"0","summary":"Jindal Worldwide  signed a share purchase agreement with June Enterprises to sell its entire 31.25% stake in Kashyap Tele-Medicines, according to an Indian bourse filing on Wednesday.The company sold 14.9 million equity shares of Kashyap Tele-Medicines for 22.4 million rupees.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO"],"gpt_icon":0},{"id":"2517190485","title":"Praxis Precision Medicines Updates on Programs and Finances","url":"https://stock-news.laohu8.com/highlight/detail?id=2517190485","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517190485?lang=en_us&edition=fundamental","pubTime":"2025-03-06 12:13","pubTimestamp":1741234402,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc. ( ($PRAX) ) has released its Q4 earnings. Here is a breakdown of the information Praxis Precision Medicines, Inc. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/praxis-precision-medicines-updates-on-programs-and-finances?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/praxis-precision-medicines-updates-on-programs-and-finances?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MDCO","PRAX"],"gpt_icon":0},{"id":"2516067575","title":"Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2516067575","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516067575?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:00","pubTimestamp":1741093200,"startTime":"0","endTime":"0","summary":"857-702-9452. Media Contact:. Dan Ferry. Life Science Advisors. Daniel@lifesci","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/04/3036474/0/en/Praxis-Precision-Medicines-to-Participate-in-Five-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","CNS","BK4561","BK4200","MDCO","BK4139","ASO","PRAX"],"gpt_icon":0},{"id":"2516635688","title":"Revolution Medicines Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2516635688","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516635688?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:16","pubTimestamp":1741007760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RVMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 03, 2025 08:16 ET (13:16 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCO","RVMD"],"gpt_icon":0},{"id":"2516638546","title":"Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $65 From $111, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2516638546","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516638546?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:37","pubTimestamp":1741005469,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines (PRAX) has an average rating of Buy and mean price target of $99.27, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO","DB","PRAX"],"gpt_icon":0},{"id":"2516708635","title":"Everest Medicines Limited's (HKG:1952) biggest owners are retail investors who got richer after stock soared 3.8% last week","url":"https://stock-news.laohu8.com/highlight/detail?id=2516708635","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516708635?lang=en_us&edition=fundamental","pubTime":"2025-03-03 12:06","pubTimestamp":1740974772,"startTime":"0","endTime":"0","summary":"Key Insights Significant control over Everest Medicines by retail investors implies that the general public has more...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-limiteds-hkg1952-biggest-owners-are-retail","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01952","BK1574","BK1583","MDCO","BK1161"],"gpt_icon":0},{"id":"2516063643","title":"Positive Outlook on Praxis Precision Medicines Amidst Phase 3 ET Program Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2516063643","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516063643?lang=en_us&edition=fundamental","pubTime":"2025-03-01 04:05","pubTimestamp":1740773118,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Ritu Baral maintained a Buy rating on Praxis Precision Medicines (PRAX – Research Report) today and set a price target of $61.00. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-outlook-on-praxis-precision-medicines-amidst-phase-3-et-program-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-outlook-on-praxis-precision-medicines-amidst-phase-3-et-program-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4590","MDCO","PRAX","BK4585","BK4561","BK4144","ET","BK4139","BK4581"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":3,"totalSize":176,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCO\",params:#limit:5,,,undefined,":[{"date":"2019-10-30","symbol":"MDCO","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/09","expectedEps":-0.84,"defaultRemindTime":1572422400000,"name":null,"time":"Pre-Market","dateTimestamp":1572408000000,"actualEps":null},{"date":"2019-07-24","symbol":"MDCO","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/06","expectedEps":-0.66,"defaultRemindTime":1563955200000,"name":null,"time":"Pre-Market","dateTimestamp":1563940800000,"actualEps":-0.67},{"market":"US","date":"2019-04-25","symbol":"MDCO","fiscalQuarterEnding":"2019/03","expectedEps":-0.71,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1556164800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2019-02-27","symbol":"MDCO","fiscalQuarterEnding":"2018/12","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1551243600000,"reportTimeType":"pre","actualEps":-0.67},{"market":"US","date":"2018-11-08","symbol":"MDCO","fiscalQuarterEnding":"2018/09","expectedEps":-0.48,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1541653200000,"reportTimeType":"pre","actualEps":-0.7}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCO\",market:\"US\",delay:false,,,undefined,":{}}}